Latest Ebos (NZX:EBO) News

Gold, rare earths and energy shares led a busy week, while major company results brought large gains and steep sell-offs. Corporate deals, new project studies and rising dividends drew buyers, but some stocks fell despite stronger earnings.

Healthcare shares delivered a mixed week, with strong gains at AVITA Medical, Australian Clinical Labs and CSL despite very different company results.
Investors also weighed new US approvals, clinical trial progress, funding needs and rising sales across the sector.

EBOS Group posted a solid FY26, growing revenue nearly 10% to $13.5 billion and underlying EBITDA 5% to $614 million, while completing a major distribution centre renewal program. The company maintains its final dividend and sets a confident growth outlook for FY27.